MedTrace Logo

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

NCT06477536 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2025-02-14

No results posted yet for this study

Summary

This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).

Conditions

  • Generalized Pustular Psoriasis

Interventions

DRUG

HB0034

300mg, i.v. Q4W

Sponsors & Collaborators

  • Shanghai Huaota Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jianzhong Zhang, PhD · Peking University People's Hospital (PKUPH)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-02
Primary Completion
2025-12-30
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06477536 on ClinicalTrials.gov